Skip to content
National Cancer Institute
U.S. National Institutes of Health
| www.cancer.gov
In English |
En español
Search
NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI
Clinical Trials Search Results
Page Options
E-Mail This Search
Clinical Trial Questions?
Get Help:
1-800-4-CANCER
or
LiveHelp online chat
Quick Links
Help Using the NCI Clinical Trials Search Form
Educational Materials About Clinical Trials
About NCI's Cancer Clinical Trials Registry
Dictionary of Cancer Terms
NCI Drug Dictionary
View Content for:
Patients
Health Professionals
Display:
Title
Description with:
Locations
Eligibility
Full Trial Description
Custom
Results 1-13 of 13 for your search:
Drug:
quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine
Find trials that include:
Any drugs shown
Trial Status:
Closed
Hide Search Criteria
Show Search Criteria
Help with Results
Select All on Page
Sort by:
Phase of Trial
Title
Type of Trial
Status of Trial
Age Range
Sponsor of Trial
Protocol IDs
Show
10
25
50
100
200
Results per Page
1.
A Study to Evaluate the Safety, Immune Response, and Efficacy of Gardasil (V501) in Women
Phase:
Phase III
Type:
Prevention
Status:
Closed
Age:
24 to 45
Sponsor:
Pharmaceutical / Industry
Protocol IDs:
2004_013
, V501-019, NCT00090220
2.
Concomitant Use of Gardasil (V501) (Human Papillomavirus [Types 6, 11, 16, 18] Recombinant Vaccine) With Combined Diphtheria, Tetanus, Pertussis Vaccine and Meningococcal Conjugate Vaccine in Adolescents
Phase:
Phase III
Type:
Prevention
Status:
Completed
Age:
11 to 17
Sponsor:
Pharmaceutical / Industry
Protocol IDs:
2005_092
, V501-025, NCT00325130
3.
Concomitant Use of Gardasil (V501, Human Papillomavirus [Types 6, 11, 16, 18] Recombinant Vaccine) With Combined Diptheria, Tetanus, Pertussis and Poliomyelitis Vaccine in Adolescents
Phase:
Phase III
Type:
Biomarker/Laboratory analysis, Prevention
Status:
Completed
Age:
11 to 17
Sponsor:
Pharmaceutical / Industry
Protocol IDs:
2005_093
, V501-024, NCT00337428
4.
Immunogenicity of GSK Bio's HPV Vaccine (580299) Versus Merck's Gardasil® in Healthy Females 18-45 Years of Age
Phase:
Phase III
Type:
Biomarker/Laboratory analysis, Prevention
Status:
Completed
Age:
18 to 45
Sponsor:
Pharmaceutical / Industry
Protocol IDs:
108933
, NCT00423046
5.
Safety, Tolerability and Immunogenicity of HPV Vaccine in Healthy Females 9 to 15 Years of Age in India.
Phase:
Phase III
Type:
Biomarker/Laboratory analysis, Prevention
Status:
Completed
Age:
9 to 15
Sponsor:
Pharmaceutical / Industry
Protocol IDs:
2006_038
, V501-029, NCT00380367
6.
An Immunogenicity and Safety Study of Gardasil® in Chinese Subjects
Phase:
Phase III
Type:
Biomarker/Laboratory analysis, Prevention
Status:
Closed
Age:
9 to 26
Sponsor:
Pharmaceutical / Industry
Protocol IDs:
2007_021
, V501-030, NCT00496626
7.
A Controlled Trial to Assess the Immunogenicity of a Proposed Paediatric Dosing Schedule of Human Papillomavirus Vaccine
Phase:
Phase III
Type:
Biomarker/Laboratory analysis, Prevention
Status:
Completed
Age:
9 to 26
Sponsor:
Other
Protocol IDs:
H07-00928
, BCGov-01, NCT00501137
8.
Broad Spectrum HPV Vaccine Dose Ranging Study
Phase:
Phase II
Type:
Biomarker/Laboratory analysis, Prevention
Status:
Completed
Age:
16 to 23
Sponsor:
Pharmaceutical / Industry
Protocol IDs:
2005_086
, V502-001, NCT00260039
9.
V501 (Gardasil) Study in Preadolescent Females
Phase:
Phase II
Type:
Biomarker/Laboratory analysis, Prevention
Status:
Closed
Age:
9 to 17
Sponsor:
Pharmaceutical / Industry
Protocol IDs:
2006_052
, V501-028, NCT00411749
10.
Phase II Pilot Study of Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine in Male Patients With HIV-1 Infection
Phase:
Phase II
Type:
Treatment
Status:
Closed
Age:
18 and over
Sponsor:
NCI
Protocol IDs:
AMC-052
, 052, NCT00513526
11.
Broad Spectrum HPV (Human Papillomavirus) Vaccine (V505) in 16 to 26 Year Old Women
Phase:
Phase II
Type:
Prevention
Status:
Closed
Age:
16 to 26
Sponsor:
Pharmaceutical / Industry
Protocol IDs:
2007_567
, V505-001, NCT00520598
12.
A Study to Evaluate Tolerability and Immunogenicity of V504 Administered Concomitantly With GARDASIL
Phase:
Phase II
Type:
Prevention
Status:
Closed
Age:
16 to 26
Sponsor:
Pharmaceutical / Industry
Protocol IDs:
2007_566
, V504-001, NCT00551187
13.
Gardasil Vaccination as Therapy in Low Grade Cervical Abnormalities
Phase:
No phase specified
Type:
Natural history/Epidemiology, Prevention
Status:
Enrolling by invitation
Age:
18 to 26
Sponsor:
Other
Protocol IDs:
DDEAMC 07-43X
, NCT00501189
Select All on Page
Help with Results
NCI Home
|
Images Version
|
Contact Us
|
Policies
|
Accessibility
|
Viewing Files
|
FOIA
|
Site Help
|
Site Map
A Service of the National Cancer Institute